The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing
- PMID: 2094606
- DOI: 10.1159/000463972
The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing
Abstract
The pharmacokinetics of Casodex have been investigated in patients with prostatic carcinoma following single oral doses of 10 mg, 30 mg and 50 mg and during daily administration at these dose levels. Casodex displays prolonged absorption following a single dose, with peak plasma concentrations observed at up to 8 h for doses of 10 mg and 30 mg and up to 48 h for the 50 mg dose. The area under the plasma concentration-time curve increased linearly with dose, and Casodex was eliminated slowly from plasma (t1/2 about 6 days). During daily administration, Casodex accumulates about 10-fold in plasma at all dose levels; this is consistent with its long plasma elimination half-life, estimated by curve fitting of these multiple dose data to be 7-10 days. Trough plasma concentrations increased linearly with dose after both single and multiple dosing, achieving mean values of 1.80, 6.89 and 9.33 micrograms/ml for the 10 mg, 30 mg and 50 mg dose levels, respectively, after 12 weeks' dosing. Neither efficiency of renal function nor age had any apparent effect on the pharmacokinetics of Casodex. The pharmacokinetics of Casodex make it ideally suited to once-daily administration.
Similar articles
-
The pharmacokinetics of Casodex in laboratory animals.Xenobiotica. 1991 Oct;21(10):1347-55. doi: 10.3109/00498259109043209. Xenobiotica. 1991. PMID: 1796611
-
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.Eur Urol. 1998;33(1):39-53. doi: 10.1159/000019526. Eur Urol. 1998. PMID: 9471040 Clinical Trial.
-
Enantioselective metabolism and pharmacokinetics of Casodex in the male rat.Xenobiotica. 1995 Jun;25(6):623-33. doi: 10.3109/00498259509061880. Xenobiotica. 1995. PMID: 7483662
-
Bicalutamide: clinical pharmacokinetics and metabolism.Clin Pharmacokinet. 2004;43(13):855-78. doi: 10.2165/00003088-200443130-00003. Clin Pharmacokinet. 2004. PMID: 15509184 Review.
-
Casodex: preclinical studies.Eur Urol. 1990;18 Suppl 3:2-9. Eur Urol. 1990. PMID: 2094608 Review.
Cited by
-
Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme.Basic Clin Pharmacol Toxicol. 2013 Aug;113(2):92-102. doi: 10.1111/bcpt.12071. Epub 2013 May 20. Basic Clin Pharmacol Toxicol. 2013. PMID: 23527766 Free PMC article.
-
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.Cochrane Database Syst Rev. 2014 Jun 30;2014(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Cochrane Database Syst Rev. 2014. PMID: 24979481 Free PMC article. Review.
-
Second generation androgen receptor antagonists and challenges in prostate cancer treatment.Cell Death Dis. 2022 Jul 21;13(7):632. doi: 10.1038/s41419-022-05084-1. Cell Death Dis. 2022. PMID: 35864113 Free PMC article. Review.
-
Bicalutamide: in early-stage prostate cancer.Drugs. 2002;62(17):2471-79; discussion 2480-1. doi: 10.2165/00003495-200262170-00006. Drugs. 2002. PMID: 12421104 Review.
-
The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function.Br J Clin Pharmacol. 1993 Oct;36(4):339-43. doi: 10.1111/j.1365-2125.1993.tb00373.x. Br J Clin Pharmacol. 1993. PMID: 12959312 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical